Deutsche Bank Reaffirms GBX 630.00 Target Price On Dunelm Group PLC (LON:DNLM), Reaffirms Hold Rating; Cyclacel Pharmaceuticals (CYCC) Shorts Lowered By 23.46%

September 8, 2017 - By Kurt Siggers

Deutsche Bank have a GBX 630.00 target price per share on the stock. The target price per share indicates a potential upside of 4.69% from Dunelm Group PLC (LON:DNLM)‘s last stock close. This rating was shown in a research note on Friday, 8 September.

Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) had a decrease of 23.46% in short interest. CYCC’s SI was 408,400 shares in September as released by FINRA. Its down 23.46% from 533,600 shares previously. With 1.26 million avg volume, 0 days are for Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC)’s short sellers to cover CYCC’s short positions. The SI to Cyclacel Pharmaceuticals Incorporated’s float is 15.7%. The stock increased 0.61% or $0.01 on September 7, reaching $1.65. About shares traded. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has risen 10.62% since September 8, 2016 and is uptrending. It has underperformed by 6.08% the S&P500.

Investors sentiment decreased to 0 in 2016 Q4. Its down Infinity, from Infinity in 2016Q3. It turned negative, as 0 investors sold Cyclacel Pharmaceuticals Inc shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 13,286 shares or 2.21% less from 13,586 shares in 2016Q3 were reported. Tower Research Cap Limited Liability Com (Trc) invested 0% of its portfolio in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC). Baker Bros Advsrs L P accumulated 13,253 shares.

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The company has market cap of $18.75 million. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. It currently has negative earnings. The Company’s family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065.

Among 17 analysts covering Dunelm Group (LON:DNLM), 8 have Buy rating, 3 Sell and 6 Hold. Therefore 47% are positive. Dunelm Group has GBX 1100 highest and GBX 515 lowest target. GBX 751.06’s average target is 24.86% above currents GBX 601.5 stock price. Dunelm Group had 144 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Dunelm Group plc (LON:DNLM) earned “Underperform” rating by RBC Capital Markets on Monday, September 21. The firm earned “Hold” rating on Thursday, September 15 by Jefferies. The firm has “Hold” rating by Deutsche Bank given on Monday, August 24. Cantor Fitzgerald maintained Dunelm Group plc (LON:DNLM) rating on Tuesday, January 26. Cantor Fitzgerald has “Buy” rating and GBX 980 target. On Wednesday, August 30 the stock rating was maintained by Peel Hunt with “Hold”. JP Morgan maintained Dunelm Group plc (LON:DNLM) on Friday, February 19 with “Overweight” rating. The company was maintained on Friday, October 9 by JP Morgan. JP Morgan maintained Dunelm Group plc (LON:DNLM) rating on Thursday, December 10. JP Morgan has “Overweight” rating and GBX 1000 target. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, September 15. The stock has “Buy” rating by Stifel Nicolaus on Thursday, January 7.

About 69,017 shares traded. Dunelm Group plc (LON:DNLM) has 0.00% since September 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Dunelm Group plc is a United Kingdom company, which operates in the homewares market. The company has market cap of 1.21 billion GBP. The Firm operates through the retail of homewares in the United Kingdom segment. It has a 14.02 P/E ratio. The Firm specializes in soft furnishings and other homeware.